|Brand names||Vicilan, Vivalan, Vivarint|
Viloxazine is a selective noradrenaline reuptake inhibitor, with a bicyclic chemistry; it possesses minimal affinity for the mAChRs, H1 and the α adrenergic receptors. It is no longer marketed in any country; it used to be marketed in Europe (including the U.K.). It is taken three times a day due its elimination half-life of 2-5 hours.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ 1.0 1.1 Pinder, RM; Brogden, RN; Speight, TM; Avery, GS (June 1977). "Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.". Drugs 13 (6): 401–21. PMID 324751. doi:10.2165/00003495-197713060-00001.
- ↑ Brayfield, A, ed. (23 September 2011). "Viloxazine Hydrochloride". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 9 August 2014.